[PDF] Top 20 Bendamustine in patients with relapsed or refractory multiple myeloma
Has 10000 "Bendamustine in patients with relapsed or refractory multiple myeloma" found on our website. Below are the top 20 most common "Bendamustine in patients with relapsed or refractory multiple myeloma".
Bendamustine in patients with relapsed or refractory multiple myeloma
... tations, as quality of response, especially the achieve- ment of cR, is considered not only a key determinant of long-term outcome for first-line therapy [29, 30], but also for salvage therapies [31-33]. the median ... See full document
7
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
... of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome in- hibitors, histone deacetylase inhibitors and monoclonal ...the ... See full document
16
Efficacy of Long Term Treatment with Low Dose Thalidomide for Patients with Relapsed/Refractory Multiple Myeloma
... in patients with newly diagnosed multiple myeloma but also relapsed/- refractory multiple myeloma ...in patients in the low-risk category, survival is not ... See full document
6
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
... with relapsed and refractory multiple myeloma (n=266), with an overall response rate of ...allows patients with advanced multiple myeloma to remain on carfilzomib for ... See full document
10
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece
... of patients achieving a response. The model randomly selects patients from the appropriate patient file based on the response distribution for each ...1000 patients are to be simulated and 10% have a ... See full document
12
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review
... Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal ...MM patients with improved ... See full document
7
Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
... MM patients eventually relapse, and the prognosis of these patients who are refractory to immunomodulatory drugs and/or bort- ezomib is very poor, highlighting the need for additional ...MM ... See full document
7
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
... 10). Patients had received a median of six prior anti-myeloma treatments (range, ...the patients were refractory to lenalidomide/bortezomib combination ...All patients received aspirin, ... See full document
8
Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
... for patients with multiple myeloma (MM) have increased during the past ...target relapsed or refractory multiple myeloma (RRMM) in order to improve disease progression, ... See full document
8
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
... for myeloma patients who have received at least two prior therapies, including bortezomib and an immunomodulatory ...diagnosed patients and efficacy versus other proteasome ...for multiple ... See full document
11
<p>Carfilzomib for relapsed and refractory multiple myeloma</p>
... in patients with renal impairment, patients with liver impairment, and patients with ...identifying patients at risk are ...in relapsed MM, as well as helping to establish best dosing ... See full document
13
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
... plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/ refractory chronic lymphocytic leukemia: results of a phase 3 random- ized double-blind ... See full document
6
Case Report A long-term favorable response and effective control of neutropenia obtained by low-dose pomalidomide treatment in a patient with relapsed refractory multiple myeloma: a case report
... of patients treated with the drug at 1 mg/day on alternate days [16]; hence, the current report is the sixth case in the world and the first report from ...Japanese patients who seem to commonly develop ... See full document
9
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
... of patients with multiple myeloma (MM) in the relapsed/refractory ...for patients with relapsed and/or refractory ...for patients with ... See full document
10
Original Article A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide
... logic malignancies. Approximately 86,000 new cases of MM were reported annually worldwide [1]. Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM. The ... See full document
5
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
... for patients with rrMM, and studies are underway evaluating its optimal dosing strategy and role in combination with other drugs used to treat this patient ... See full document
11
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
... study. Patients were stratified according to their renal func- tion (Group 1 [CrCl ...Thirty-five patients discontinued the study (22 due to progressive disease and 6 due to adverse events [sep- sis, ... See full document
8
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
... the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory ...of patients with relapsed and refractory ...for patients with relapsed/ refractory ... See full document
16
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
... Abstract: Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma ...MM patients in both the frontline and recurrent ...in patients ... See full document
8
Original Article Efficacy and safety of pegylated liposomal doxorubicin for multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
... for multiple myeloma. Compared with no PLD for patients with relapsed or refractory myeloma, PLD can inhibit disease progression and increase VGPR rate, but does not improve ... See full document
13
Related subjects